Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias

Clinical trial NCT07765966 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07765966
Sponsor: RiboX Therapeutics Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed or Refractory Autoimmune Cytopenias Immune Thrombocytopenia (ITP)

Start date: 2027-02-01
Primary completion: 2028-06-30
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.